Why Actinogen Medical shares climbed 466% on excitement over an Alzheimer's treatment

An Alzheimer's treatment is one of medicine's last great frontiers.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Actinogen Medical Ltd (ASX: ACW) share price is up 466% today from 0.9 cents to 5.1 cents after the biotech researcher reported positive clinical trial results for its Xanamem drug designed to treat cognitive impairment in the elderly.

According to the company's announcement its trial reached a "statistically significant" endpoint in treating patients with 20mg daily dose of Xanamem for 12 weeks, compared to placebo.

Moreover, the company claims the printed dataset advances its drug development strategy for the treatment of Alzheimer's and other neurological diseases. 

Treating Alzheimer's is commonly described as one of the last great medical frontiers as it's one of the most prevalent human diseases still with no recognised treatment or cure.

As such share markets globally are littered with the shells of biotech hopefuls that have claimed to develop treatments only for trial results to prove ineffective. 

Back in March 2019 shares in US biotech giant Biogen crashed after it ended the trials into its own Alzheimer's drug that Goldman Sachs had previously told investors should generate US$12 billion a year in sales. Oops.

While shares in ASX listed Prana Biotechnology (ASX: PBT) went gangbusters to hit a high around $1.26 in 2014 only to sell for 3.3 cents today under a new name of Alterity Therapeutics Ltd (ASX: ATH).

Prana shares bombed after its much vaunted Phase II Alzheimer drug trials failed on almost every count. 

Some medical professionals have even claimed the the neuro-degenerative and genetic nature of Alzheimer's or Huntington's mean a treatment will never be found. 

As such we can see this is a high risk, but high reward space if any biotech ever does crack what is probably the largest unmet single medical market left. As you can probably guess I would not suggest buying Actinogen shares. 

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »